Stifel lowered the firm’s price target on Alto Neuroscience (ANRO) to $10 from $32 and keeps a Buy rating on the shares. The firm notes its lowered target reflects the failure of ALTO-100, but it continues to see the stock’s risk/reward as “compelling,” especially as it relates to ALTO-300, which employs a biomarker strategy in an attempt to enrich for better efficacy with agomelatine, an approved antidepressant in Europe.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio